ReviewMolecular biology reports2025
CircRNAs: emerging players in tyrosine kinase inhibitor resistance mechanisms in solid tumors.
Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Circular RNAs: emerging regulators of oxaliplatin response and resistance in cancer therapy.Medical oncology (Northwood, London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of several malignancies, including both hematological malignancies and solid tumors. However, the development of resistance to TKIs is a key clinical challenge, resulting in disease progression and therapeutic failure. CircRNAs, a class of covalently closed non-coding RNA molecules, are now recognized as key players in this process. Dysregulation of circRNAs leads to TKI resistance by influencing key pathways such as apoptosis, autophagy, epithelial-mesenchymal transition, and alternative kinase activation. While challenges in clinical translation persist, advances in RNA-targeted technologies and detailed mechanistic assays are expected to enable application of circRNA-based interventions to overcome TKI resistance. This review summarizes the current knowledge on circRNAs in the context of TKI resistance in solid tumors, highlighting their functional roles, fundamental mechanisms, and possible clinical applications in bypassing drug resistance and refining cancer therapy outcomes.
Indexed as
Identifiers
40767933What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.